Organization
NYU Langone Perlmutter Cancer Center
5 abstracts
Abstract
Long-term outcomes of pembrolizumab (pembro) in combination with gemcitabine (gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial cancer of the bladder (MIUC): A multicenter phase 2 trial.Org: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, University of Chicago Comprehensive Cancer Center, Chicago, IL, University of Michigan Rogel Comprehensive Cancer Center, Memorial Sloan Kettering Cancer Center, Lineberger Comprehensive Cancer Center,
Abstract
Tissue and plasma-based mechanisms of resistance to first-line osimertinib in EGFR-mutant NSCLC: A multi-institutional cohort.Org: Massachusetts General Hospital, Harvard Medical School, Boston, MA, Columbia University Irving Medical Center, New York, NY, USA, New York, NY,
Abstract
Using patient-reported outcomes to assess the impact of germline genetic testing on prostate cancer patients.Org: Invitae, Carolina Urologic Research Center and Atlantic Urology Clinics, University Urology Associates, Associated Medical Professionals of NY, AUI Health—Advanced Urology Institute,
Abstract
Real-world clinical outcomes in a U.S. Asian population with stage IV NSCLC treated with osimertinib (Osi) stratified by EGFR subtype.Org: NYU Langone Health, New York, NY, NYU Grossman School of Medicine, Department of Population Health, New York Oncology Hematology PC, Nykode Therapeutics, New York University School of Medicine,
Abstract
Preliminary results from the Female Asian Nonsmoker Screening Study (FANSS).Org: NYU Langone Perlmutter Cancer Center, NYU Perlmutter Cancer Center, Massachusetts General Hospital, Chao Family Comp Cancer Ctr, NYU Grossman School of Medicine, Department of Population Health,